Literature DB >> 20055087

Haemolytic activity of liposomes: effect of vesicle size, lipid concentration and polyethylene glycol-lipid or arsonolipid incorporation.

Spyridon Mourtas1, Georgios P A K Michanetzis, Yannis F Missirlis, Sophia G Antimisiaris.   

Abstract

The haemolysis caused by various types of liposomes was measured after incubation of liposomes with human red blood cell (erythrocyte) suspension. Liposomes composed of phospholipids and containing or not arsonolipids (arsonoliposomes) were tested. In some cases liposomes that were coated with polyethylene glycol (MW 2000), which were formulated by including 8 mol% DSPE-PEG2000 in their lipid membrane, were used. Multilamellar vesicles were prepared by the thin film hydration technique (conventional liposomes) or by the one-step technique (arsonoliposomes). Sonicated vesicles were produced by probe sonication of the initial liposome preparations. Phospholipid concentration in the liposome dispersions were measured by the Stewart assay, and adjusted accordingly. Haemolysis was measured after incubating 100 microl of liposome dispersions with 900 microl of red blood cell suspension (blood) for 1 h. The results reveal that the haemolysis caused, when liposomes are incubated in blood at concentrations below 0.16 mg (lipid)/ml (blood), was minimum. Only in case of Pegylated arsonoliposomes, significant haemolysis percents were observed. At higher lipid concentrations, 0.38 or 0.6 mg/ml, the haemolysis caused by arsonoliposomes was substantially increased, even in the cases of non-Pegylated arsonoliposomes. In most cases, especially when arsonolipid-containing liposomes were evaluated, vesicle size also had considerable effect on vesicle-induced haemolysis. Nevertheless, at concentrations which are relevant with liposomal drug administration in humans, all formulations tested demonstrated negligible haemolysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20055087     DOI: 10.1166/jbn.2009.1050

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  4 in total

1.  Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.

Authors:  Raghavendra Gowda; SubbaRao V Madhunapantula; Arati Sharma; Omer F Kuzu; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2014-07-31       Impact factor: 6.261

2.  Rhamnolipid-Based Liposomes as Promising Nano-Carriers for Enhancing the Antibacterial Activity of Peptides Derived from Bacterial Toxin-Antitoxin Systems.

Authors:  Beatriz Cristina Pecoraro Sanches; Camila Aguiar Rocha; Jose Gregorio Martin Bedoya; Vinicius Luiz da Silva; Patrícia Bento da Silva; Ana Marisa Fusco-Almeida; Marlus Chorilli; Jonas Contiero; Edson Crusca; Reinaldo Marchetto
Journal:  Int J Nanomedicine       Date:  2021-02-10

3.  Impact of Liposomal Drug Formulations on the RBCs Shape, Transmembrane Potential, and Mechanical Properties.

Authors:  Sylwia Cyboran-Mikołajczyk; Przemysław Sareło; Robert Pasławski; Urszula Pasławska; Magdalena Przybyło; Kacper Nowak; Michał Płóciennik; Halina Podbielska; Marta Kopaczyńska; Magdalena Wawrzyńska
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

4.  Stealth lipid polymer hybrid nanoparticles loaded with rutin for effective brain delivery - comparative study with the gold standard (Tween 80): optimization, characterization and biodistribution.

Authors:  Rania A H Ishak; Nada M Mostafa; Amany O Kamel
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.